The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study

Therapeutic options are limited in relapsed/refractory acute myeloid leukemia (AML). We evaluated the maximum tolerated dose (MTD) and preliminary efficacy of mammalian target of rapamycin (mTOR) inhibitor, everolimus (days 5–21) in combination with azacitidine 75 mg/m(2) subcutaneously (days 1–5 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Peter, Tiong, Ing Soo, Fleming, Shaun, Pomilio, Giovanna, Cummings, Nik, Droogleever, Mark, McManus, Julie, Schwarer, Anthony, Catalano, John, Patil, Sushrut, Avery, Sharon, Spencer, Andrew, Wei, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581027/
https://www.ncbi.nlm.nih.gov/pubmed/28881728
http://dx.doi.org/10.18632/oncotarget.13699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581027/
https://www.ncbi.nlm.nih.gov/pubmed/28881728
http://dx.doi.org/10.18632/oncotarget.13699

Ejemplares similares